This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Updated from 2:37 p.m. EDT

Shares of Isolagen (ILE) were among the worst-performing health-related stocks Monday, falling 25% after the company announced the resignation of its chief executive.

Robert Bitterman, who joined the company in September 2004, served as CEO for less than eight months. The company did not offer an explanation for Bitterman's departure. The news comes just a week after the company appointed a new chief financial officer. Isolagen has retained recruiting firm Borman, Golding to assist the company in finding and hiring a new chief executive to succeed Bitterman. Shares traded down $1.47 to $4.41.

Adventrx Pharmaceuticals (ANX) traded actively after the company received Food and Drug Administration clearance to begin a phase III clinical trial of its CoFactor treatment for metastatic colorectal cancer. CoFactor is designed to enhance the activity of the widely used cancer drug 5-fluorouracil. The study is expected to include about 600 patients, half of whom will receive a CoFactor combination therapy. The primary endpoint for the study is progression free survival, which is defined as the time from start of treatment to time of disease progression or death. Shares traded down 7 cents to $2.78 on volume of 2.1 million shares.

Shares of Sepracor (SEPR) rose 1.6% after the company posted a first-quarter loss that was smaller than expected. The pharmaceutical company posted a loss of $22.6 million, or 22 cents a share, on sales of $119 million. Analysts polled by Thomson First Call were expecting a loss of 60 cents a share on sales of $111 million. A year ago, the company posted a loss of $50.4 million, or 59 cents a share, on sales of $99.5 million. Last year's results included a charge of $30.7 million, or 36 cents a share. Shares traded up 97 cents to $61.25.

Endologix (ELGX) fell 4.4% after the medical device maker posted a wider first-quarter loss. The company reported a loss of $3.3 million, or 10 cents a share, on sales of $1.4 million. Analysts were expecting a smaller loss of 8 cents a share on sales of $1.7 million. A year ago, the company posted a loss of $2 million, or 7 cents a share, on sales of $820,000. Endologix said the wider year-over-year loss was caused by costs associated with the build out and training of its domestic sales force and by expenses related to Sarbanes-Oxley compliance. Shares traded down 22 cents to $4.83.

Other health-care volume movers included Pfizer (PFE), down 19 cents to $27.03; Elan (ELN), up 20 cents to $4.06; Amgen (AMGN), down 86 cents to $58.03; Merck (MRK), down 28 cents to $33.92; Johnson & Johnson (JNJ), up 5 cents to $68.54; Schering-Plough (SGP), down 5 cents to $20.70; Intuitive Surgical (ISRG), down $2.28 to $43.50; and Genentech (DNA), down 41 cents to $69.43.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs